NCT04313335

Duloxetine for PHN

Prophylactic Duloxetine Administration During Acute Herpes Zoster Prevents Postherpetic Neuralgia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 750 (actual)
• Sponsor: Beijing Tiantan Hospital · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

In this study, the investigators aim to investigate the preventive efficacy of prophylactic oral duloxetine during acute herpes zoster on postherpetic neuralgia and its safety.

Detailed description

Postherpetic neuralgia is a common complication of herpes zoster. Several interventions have been investigated for the treatment of postherpetic neuralgia, however, there is a lack of preventive intervention on postherpetic neuralgia. A recent retrospective study revealed that the administration of gabapentin during the acute herpes zoster period significantly decreased the incidence of postherpetic neuralgia. In the present study, the investigators aim to conduct a prospective, randomized, open-label, endpoint blinded study to investigate the preventive efficacy of prophylactic use of duloxetine on postherpetic neuralgia.

Conditions

• Postherpetic Neuralgia

Interventions

Type	Name	Description
DRUG	Duloxetine	Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.

Timeline

• Start date: 2021-03-01
• Primary completion: 2023-05-16
• Completion: 2023-05-16
• First posted: 2020-03-18
• Last updated: 2024-01-09

Locations

1 site across 1 country: China